Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

J. Feld, Jordan; V. Kowdley, Kris; Coakley, Eoin; H. Sigal, Samuel; R. Nelson, David; H. Crawford, Dorothy; Weiland, Ola; Aguilar, Humberto; Xiong, Junyuan; Pilot-Matias, Tami; DaSilva-Tillmann, Barbara; Larsen, Lois; Podsadecki, Thomas; Bernstein, Barry

doi:10.1056/nejmoa1315722

Public

Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

Published in New England Journal of Medicine • Apr 11, 2014

Authors:

Jordan J. Feld

Kris V. Kowdley

Eoin Coakley

Abstract

BACKGROUND: The interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r) and the NS5A inhibitor ombitasvir (also known as ABT-267) plus the nonnucleoside polymerase inhibitor dasabuvir (also known as ABT-333) and ribavirin has shown efficacy against the hepatitis C vi...

Subject

Dasabuvir

Ombitasvir

Ribavirin

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!